It’s been called a “silent epidemic” that’s slowly wasting away the livers of millions of Americans while doctors have a paltry understanding of the disease and no approved treatments.

Non-alcoholic steatohepatitis, or Nash, is now in the sights of more than a dozen drugmakers. Allergan plc (NYSE: AGN) became the latest, announcing two deals to acquire Nash treatments in less than 12 hours. It’s racing companies from startup Intercept Pharmaceuticals Inc. (Nasdaq: ICPT) to giants including Gilead Sciences Inc. (Nasdaq: GILD) and Pfizer Inc. (NYSE: PFE) to reach an untapped market that could be worth $5 billion to $10 billion a year, according to a May estimate by RBC Capital Markets Corp. analyst Michael Yee.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.